Monograph

J01DI02 - Ceftaroline Fosamil

Not porphyrinogenic

Side effects

Common adverse reactions of ceftaroline that can be confused with an acute porphyric attack are diarrhoea, nausea, vomiting and abdominal pains. These side effects may potentially be porphyrinogenic if leading to a decrease in carbohydrate intake.

Rationale

Ceftaroline is not a substrate, inhibitor or inducer of CYP450 enzymes. No pharmacokinetic porphyrinogenic effects are suspected.

Chemical description

Cephalosporin antibiotic

Therapeutic characteristics

Ceftaroline is indicated for the treatment of complicated skin and soft tissue infections (cSSTI) and community acquired pneumonia (CAP). It is administered by intravenous infusion. Terminal elimination half-life is 2.5 hours.

Metabolism and pharmacokinetics

Ceftaroline fosamil is a prodrug that is converted into the active drug ceftaroline in plasma by phosphatase enzymes (SPC). It is mainly excreted renally (88 %). Ceftaroline is not metabolized by CYP450 enzymes and is not suspected to be an inhibitor or inducer of CYP450 enzymes (Laudano 2011, SPC). No drug-drug interactions with ceftaroline as a perpetrator have been reported in the literature (Lexi-Interact).

References

#	Citation details	PMID
*	Scientific articles
1.	Ceftaroline fosamil: a new broad-spectrum cephalosporin. Laudano JB. J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii11-8.	21482565
*	Government bodies
2.
*	Drug interaction databases
3.	Lexi-Interact in UpToDate. Ceftaroline fosamil: Drug interaction program.
*	Summary of Product Characteristics
4.	The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). (Zinforo).

Citation details

PMID

Scientific articles

Ceftaroline fosamil: a new broad-spectrum cephalosporin.

Laudano JB. J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii11-8.

21482565

Government bodies

Drug interaction databases

Lexi-Interact in UpToDate. Ceftaroline fosamil: Drug interaction program.

Summary of Product Characteristics

The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). (Zinforo).

Similar drugs

Explore alternative drugs in similar therapeutic classes J01D / J01DI or go back.

Tradenames and packages

From some sources, we get a list of packages (United Kingdom, Ireland, Estonia). Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway). What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names are the searchable terms. The gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Netherlands